BioNTech and OncoC4’s Gotistobart Nearly Doubles Survival in Previously Treated Squamous NSCLC
Updated PRESERVE-003 data showed median overall survival of 18.5 months with the CTLA-4 antibody, compared with 10 months for docetaxel. The result is encouraging, but confirmation must come from the ongoing pivotal stage of the Phase 3 trial. BioNTech…
Forlong Biotech’s Pre-B Financing Reaches Nearly RMB 200 Million as It Prepares FL115 for Phase 3 Bladder Cancer Trial
Forlong Biotech has completed the second close of its Pre-B financing, bringing the round’s total to nearly RMB 200 million. Fosun Health Capital’s new drug fund led the latest close, which raised more than RMB 100 million, according to Chinese financing…
RemeGen and AbbVie’s RC148 Delivers 90% Response Rate in a Phase 1b Trial of First-Line Squamous NSCLC
The PD-1/VEGF bispecific antibody produced high response rates with chemotherapy across squamous and non-squamous lung cancer cohorts, supporting its advancement into Phase 3 development. RemeGen and AbbVie have reported strong early clinical results for…
Roche and MediLink’s Tam-Peli Reduces Death Risk by 54% in Phase 3 Small-Cell Lung Cancer Trial
Roche and MediLink Therapeutics have reported a substantial survival benefit for tambotatug pelitecan, the experimental B7-H3-targeted antibody-drug conjugate known as Tam-Peli, in patients with relapsed small-cell lung cancer. In the Chinese Phase 3…
Biokin’s Iza-Bren Shows Activity in Previously Treated EGFR-Mutated Lung Cancer, Supports Global Registrational Dose
Biokin’s U.S. subsidiary SystImmune has reported new global Phase 1 results for iza-bren, its EGFR×HER3 bispecific antibody-drug conjugate (ADC), supporting selection of a dose for registrational testing in patients with previously treated EGFR-mutated…
GSK and Hansoh’s Ris-Rez Cuts Risk of Death by 54% in Phase 3 Small-Cell Lung Cancer Trial
GSK and Hansoh Pharma’s B7-H3-directed antibody-drug conjugate risvutatug rezetecan delivered a striking survival benefit in relapsed small-cell lung cancer, potentially setting a new benchmark for a disease in which treatment progress has historically…
Windward Bio’s WIN378 Delivers Positive Phase 2 Asthma Data as Twice-Yearly Anti-TSLP Antibody Moves Into Phase 3
Windward Bio has reported positive interim Phase 2 results for WIN378, also known as HBM9378 or SKB378, showing sustained improvements in lung function and key inflammatory biomarkers after a single dose in patients with uncontrolled asthma. With a…
Clover Biopharma’s RSV-hMPV-PIV3 Combination Vaccines Deliver Encouraging Phase 2 Results in Older Adults
Clover Biopharmaceuticals has reported positive preliminary Phase 2 data for SCB-1022 and SCB-1033, two next-generation combination respiratory vaccines designed to protect older adults against multiple major respiratory viruses with a single shot. The…
CTTQ’s HER2 Bispecific ADC TQB2102 Hits Phase 3 Endpoints in HER2-Low Breast Cancer, Setting Up China Filing
Chia Tai Tianqing Pharmaceutical Group (CTTQ), a core subsidiary of Sino Biopharmaceutical, has reported a major late-stage clinical win for TQB2102 (rolditamig deuderuxtecan), its internally developed HER2 bispecific antibody-drug conjugate (ADC). The…
Akeso’s Ivonescimab Outshines Pembrolizumab on Overall Survival in Phase 3 HARMONi-2 Trial
China’s Akeso has reported another major clinical milestone for ivonescimab (AK112), its first-in-class PD-1/VEGF bispecific antibody, announcing that the drug demonstrated a statistically significant and clinically meaningful overall survival (OS)…